Loading
A phase 1/2 trial of gemcitabine and nab-paclitaxel in pancreatic cancer, run by Washington University School of Medicine, now recruiting.
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma is a phase 1/2, randomised interventional study registered as NCT06904378 by Washington University School of Medicine, with a registry enrolment figure of 61 participants, started 2026-03-25 and due to reach its primary completion in 2028-09-30. Interventions recorded: ONT01; Gemcitabine; Nab paclitaxel. Conditions listed: Metastatic Pancreatic Ductal Adenocarcinoma. Primary outcome: Recommended phase II dose (RP2D) (Phase I only); Number of participants with dose-limiting toxicities (DLTs) (Phase I only); Progression-free rate at 6 months (RP2D participants in Phase I and Phase II participants only). Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed adenocarcinoma of the pancreas". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.